Homocysteine and cardiovascular disease: A 17-year follow-up study in Busselton

European Journal of Preventive Cardiology

Volumn 11, Issue 4, 2004, Pages 350-351

  O'leary, Colleen M ^a   Knuiman, Matthew W ^a   Divitini, Mark L ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

cardiovascular diseases; cohort study; Cox proportional hazards regression; homocysteine

Indexed keywords

HOMOCYSTEINE;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; HUMAN; MALE; MEDICAL ASSESSMENT; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGRESSION ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; AUSTRALIA; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CEREBROVASCULAR ACCIDENT; CONFOUNDING FACTORS (EPIDEMIOLOGY); CORONARY DISEASE; CREATININE; FEMALE; FOLLOW-UP STUDIES; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS;

EID: 4344712331     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/01.hjr.0000136457.36990.1a     Document Type: Article

References (12)

1. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease: The European concerted action project. JAMA 1997; 277: 1775–1781.
2. Knekt P, Teunanen A, Alfthan G, et al. Hyperhomocystinemia: A risk factor or a consequence of coronary heart disease? Arch Intern Med 2001; 161: 1589–1594.
3. Fallon UB, Ben-Shlomo Y, Elwood P, et al. Homocysteine and coronary heart disease in the Caerphilly cohort: a 10 year follow up. Heart 2001; 85: 153–158.
4. Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995; 24: 704–709.
5. Folsom AR, Nieto FJ, McGovern PG, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B Vitamins. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1998; 98: 204–210.
6. DeBree A, Verschuren WMM, Blom HJ, Nadeau M, Trijbels FJM, Kromhout D. Coronary heart disease mortality, plasma homocysteine, and B-vitamins: a prospective study. Atherosclerosis 2003; 166: 369–377.
7. Wald NJ, Watt HC, Law MR, Weir DG, McPartlin J, Scott JM. Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. Arch Intern Med 1998; 158: 862–867.
8. De Bree A, Verschuren WMM, Kromhout D, et al. Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary heart disease. Pharmacol Rev 2002; 54: 599–618.
9. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: Evidence on causality from a meta-analysis. BMJ 2002; 325: 1202.
10. The Homocysteine Studies Collaboration Homocysteine and risk of ischemic heart disease and stroke. A meta-analysis. JAMA 2002; 288: 2015–2022.
11. Coles KA, Knuiman MW, Plant AJ, Riley TV, Smith DW, Divitini ML. A prospective study of infection and cardiovascular diseases: The Busselton Health Study. Eur J Cardiovasc Prev Rehabil 2003; 10: 278–282.
12. Mann JFE, Gerstein HC, Dulau-Florea I, Lonn E. Cardiovascular risk in patients with mild renal insufficiency. Kidney Internat 2003; 63(S84): S192–S196.